Masteron Profile UK

5418
Articles

masteron

Well absorbed through the conjunctiva. The concentration in the central nervous system is achieved in 0.5 – 1 hour. Plasma protein binding is moderate. The masteron is 2 hours.

Indications for diagnostic purposes: when ophthalmoscopy; when determining refraction. In inflammatory diseases of the front eye section – episcleritis, sclerites, keratitis, iridocyclitis, uveitis – in the complex therapy.

Contraindications:
Hypersensitivity to the drug, angle-closure glaucoma, suspicion of glaucoma, post-traumatic paresis of the sphincter of the pupil, children under 3 years of age, pregnancy, lactation. Precautions Advanced age, intestinal obstruction, prostatic hyperplasia.

Dosing and Administration
Locally.
Adults and children:

  • For diagnostic purposes masteron: 1-2 drops of each drug in the conjunctival sac, the dose was repeated if necessary after 5-10 min.
  • To achieve cycloplegic refraction in the study: 2-3 times a day at intervals 1-2 drops 15-20 minutes.
  • In inflammatory diseases: 1 drop three times a day for 5-10 days, in severe cases, permitted the use of 1 drop every 3-4 hours.

 

Side effects Local reactions: burning sensation, redness, swelling of the conjunctiva and the eyeball, photophobia, increased intraocular pressure, reduced visual acuity, Blepharoconjunctivitis, punctate keratitis. In rare cases, symptoms of systemic effects (more children), weakness, nausea, dry mouth, dizziness, headache, somnolence, tachycardia, intestinal atony, atonic bladder, acute urinary retention.

Overdose Symptoms: violation of psychic reactions and conduct disorder (incoherent speech, hallucinations, seizures, disorientation in time and space, changing emotional state), ataxia, excessive fatigue, violation of recognition of objects at close range, the coma (or death). Treatment: intravenous specific antidote – physostigmine children at a dose of 0.5 mg if necessary (with no effect after 5 min) repeat dose (maximum dose should not exceed 2 mg); antidote is administered oral masteron to adults at a dose of 2 mg, with no effect after 20 minutes was repeated administration at a dose of 2.1 mg.

Interaction with other drugs
decreases effect of M-cholinomimetics and cholinesterase inhibitors. Cyclopentolate Effect increase agonists.

Cautions
In applying  need to control intraocular pressure. To reduce the risk of systemic side effects is recommended slight pressure with your finger on the projection area of the lacrimal sac at the inner corner of the eye for 1-2 minutes after installing the product.
Effects on ability to drive and use machines During treatment with masteron advised not to drive vehicles and engage in potentially hazardous activities that require a rapid psychomotor reactions.

Product form
Eye drops 1%.
In 5 ml of solution in a white polymer bottle-dropper indoor polymer cap with safety ring. One dropper bottle with instructions for use in a carton box.